Abstract:Introduction: Immunogenicity refers to the ability of a substance, such as a therapeutic drug, to elicit an immune response. While beneficial in vaccine development, undesirable immunogenicity can compromise the safety and efficacy of therapeutic proteins by inducing anti-drug antibodies (ADAs). These ADAs can reduce drug bioavailability and alter pharmacokinetics, necessitating comprehensive immunogenicity risk assessments starting at early stages of drug development. Given the complexity of immunogenicity, an integrated approach is essential, as no single assay can universally recapitulate the immune response leading to the formation of anti-drug antibodies. Methods: To better understand the Dendritic Cell (DC) contribution to immunogenicity, we developed two flow cytometry-based assays: the DC internalization assay and the DC activation assay. Monocyte-derived dendritic cells (moDCs) were generated from peripheral blood mononuclear cells (PBMCs) and differentiated over a five-day period. The internalization assay measured the accumulation rate of therapeutic antibodies within moDCs, while the activation assay assessed the expression of DC activation markers such as CD40, CD80, CD86, CD83, and DC-SIGN (CD209). To characterize these two assays further, we used a set of marketed therapeutic antibodies. Results: The study highlights that moDCs differentiated for 5 days from freshly isolated monocytes were more prone to respond to external stimuli. The internalization assay has been shown to be highly sensitive to the molecule tested, allowing the use of only 4 donors to detect small but significant differences. We also demonstrated that therapeutic antibodies were efficiently taken up by moDCs, with a strong correlation with their peptide presentation on MHC-II. On the other hand, by monitoring DC activation through a limited set of activation markers including CD40, CD83, and DC-SIGN, the DC activation assay has the potential to compare a series of compounds. These two assays provide a more comprehensive understanding of DC function in the context of immunogenicity, highlighting the importance of both internalization and activation processes in ADA development. Discussion: The DC internalization and activation assays described here address key gaps in existing immunogenicity assessment methods by providing specific and reliable measures of DC function. The assays enhance our ability to pre-clinically evaluate the immunogenic potential of biotherapeutics, thereby improving their safety and efficacy. Future work should focus on further validating these assays and integrating them into a holistic immunogenicity risk assessment framework.

Assessment of Surface Markers and Functionality of Dendritic Cells (DCs)

Human Monocyte-Derived Dendritic Cells Expressing Both Chemotactic Cytokines IL-8, MCP-1, RANTES and Their Receptors, and Their Selective Migration to These Chemokines.

Flow cytometry-assisted analysis of phenotypic maturation markers on an immortalized dendritic cell line

Phenotypic and functional characteristics of dendritic cells derived from human peripheral blood monocytes

MONOCYTE-DERIVED DENDRITIC CELLS ISOLATION AND PHENOTYPIC CHARACTERIZATION

The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells.

GM-CSF Monocyte-Derived Cells and Langerhans Cells As Part of the Dendritic Cell Family

Investigating Evolutionary Conservation of Dendritic Cell Subset Identity and Functions

Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies

Development and characterization of dendritic cell internalization and activation assays contributing to the immunogenicity risk evaluation of biotherapeutics

The lifespan and kinetics of human dendritic cell subsets and their precursors in health and inflammation

Antigen Presenting Properties of a Myeloid Dendritic-Like Cell in Murine Spleen

Characterization of human skin-derived CD1a-positive lymph cells

Dendritic Cells: Origin and Differentiation

Expression analysis of surface molecules on human thymic dendritic cells with the 10th HLDA Workshop antibody panel

Utilizing murine dendritic cell line DC2.4 to evaluate the immunogenicity of subunit vaccines in vitro

Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products

The Acquisition of Antigen Cross-Presentation Function by Newly Formed Dendritic Cells

Evaluating in vivo approaches for studying the roles of thymic DCs in T cell development in mice

Development of Dendritic Cell System.

Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8α+ dendritic cells